Lifshitz Law PLLC Announces Investigations of QUMU, CINC, HZN, and MPB
January 14, 2023 20:08 ET
|
Lifshitz Law Firm, P.C.
NEW YORK, Jan. 14, 2023 (GLOBE NEWSWIRE) -- Qumu Corporation (NASDAQ: QUMU) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of...
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DCT, ALBO, CINC, AMYT
January 13, 2023 20:00 ET
|
Monteverde & Associates PC
NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Lifshitz Law PLLC Announces Investigations of QUMU, CINC, HZN, and MPB
January 11, 2023 19:07 ET
|
Lifshitz Law Firm, P.C.
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Qumu Corporation (NASDAQ: QUMU) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
January 10, 2023 10:07 ET
|
Brodsky & Smith LLC
BALA CYNWYD, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMYT, CINC, ALBO
January 10, 2023 08:27 ET
|
Halper Sadeh LLC
NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
CinCor Pharma to be Acquired by AstraZeneca
January 09, 2023 02:05 ET
|
CinCor Pharma Inc
WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has...
CinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled Hypertension
November 28, 2022 07:30 ET
|
CinCor Pharma, Inc.
Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a...
CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences
November 22, 2022 18:44 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:...
CinCor Pharma to Present at Upcoming Jefferies London Healthcare Conference
November 09, 2022 08:00 ET
|
CinCor Pharma, Inc.
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking...
CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions
November 07, 2022 17:09 ET
|
CinCor Pharma, Inc.
Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in...